ArticleCurrent oncology (Toronto, Ont.)2019

Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre.

K Uminski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.